PSMA-PET/CT for Prostate Cancer (NGP1)

Prostate cancer is the most frequently occurring male cancer in Belgium. Patients who have been treated for prostate cancer, i.e. by surgery and/or radiotherapy, in a substantial degree suffer from a tumor recurrence, often diagnosed by an increase in serum tumor marker PSA (prostate specific antigen) within the first few years. In these patients with evidence of a tumor recurrence after primary treatment, it is important to most exactly define the location(s) of tumor, to guide appropriate therapy by surgery, radiotherapy and/or hormonotherapy. In so-called oligo-metastatic disease targeted therapy may still be curative and prevent the disease from spreading to distant locations. Therefore it is of paramount importance to have an accurate tool of medical imaging to localize all possible locations to be treated.

With some patients, the PSA-value is so low, that conventional nuclear medicine bone scanning or radiological CT or MRI cannot determine where the metastases are. Therefore, [18F]-Choline PET-CT was introduced to improve diagnostic imaging performance. However, in 30 to 40 percent of patients choline-PET does not localize tumor either, especially in small tumors and/or very low PSA values.

The PSMA PET is already routinely used in many European centres, and has shown a superior accuracy in these patients as compared to conventional imaging techniques. This has been a very consistent finding in scientifically reported patient studies.

Most of these investigations have been performed with PSMA labeled with Gallium-68. The investigators in Ghent, as others, have labeled PSMA with Fluor-18. This tracer provides many advantages, including a higher production yield enabling more patients to be scanned. Also from a perspective of radioprotection and financial costs, Fluor-18 is a better choice. Moreover, several recent studies, comparing Fluor with Gallium modalities seem to suggest equivalent or better diagnostic results, possibly because of a lower aspecific background activity.

Study Overview

• Status: Completed
• Conditions: Prostate Cancer
• Intervention / Treatment: Diagnostic test: 18F-PSMA

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

Study Locations

• Belgium
  • Gent, Belgium
    • University Hospital, Ghent

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Patients diagnosed with prostate cancer, either in the setting of diagnosis of biochemical recurrence after curative treatment (prostatectomy with or without lymphadenectomy or radiotherapy), or at primary diagnosis and staging.

Exclusion Criteria:

• Age < 40 or > 70 years in phase-1; upper age limit is not applicable for the phase-2 trial.

Most patients will be > 65 years old, an estimate may be more than 80%.

• Physically or mentally unfit to perform the sequential procedures
• Refusal of patient to be informed about accidental findings on scans.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: DIAGNOSTIC
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: study group	Diagnostic test: 18F-PSMA; 18F-PET imaging

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of administration - follow up of adverse events	Follow up of treatment-related adverse events according to CTCAE v4.0 criteria.	Adverse events are followed up until 24 hours after PSMA administration.
Safety of administration - change in blood pressure	Changes in blood pressure (systolic and diastolic, expressed in mm Hg)	hourly checking of blood pressure from timepoint of 18F-PSMA-11 injection up to 5 hours post 18F-PSMA injection
Safety of administration - change in temperature	Changes in temperature (expressed in °C)	hourly checking of temperature from timepoint of 18F-PSMA-11 injection up to 5 hours post 18F-PSMA injection
Safety of administration - change in heart rate	Changes in heart rate (expressed in beats per min)	hourly checking of heart rate from timepoint of 18F-PSMA-11 injection up to 5 hours post 18F-PSMA injection
Safety of administration - erythrocytes	Changes in erythrocytes count in plasma (expressed in 10^6/µL)	before and 300 minutes after 18F-PSMA administration
Safety of administration - haemoglobin	Changes in haemoglobin concentration in plasma (expressed in g/dL)	before and 300 minutes after 18F-PSMA administration
Safety of administration - leukocytes	Changes in leukocytes count in plasma (expressed in 10^3/µL)	before and 300 minutes after 18F-PSMA administration
Safety of administration - thrombocytes	Changes in thrombocytes count in plasma (expressed in 10^3/µL)	before and 300 minutes after 18F-PSMA administration
Safety of administration - sodium	Changes in sodium concentration in serum(expressed in mmol/L)	before and 300 minutes after 18F-PSMA administration
Safety of administration - creatinine	Changes in creatinine concentration in serum (expressed in mg/dL)	before and 300 minutes after 18F-PSMA administration
Safety of administration - AST	Changes in AST concentration in serum (expressed in U/L)	before and 300 minutes after 18F-PSMA administration
Safety of administration - ALT	Changes in ALT concentration in serum (expressed in U/L)	before and 300 minutes after 18F-PSMA administration
Safety of administration - Alkaline phosphatase	Changes in alkaline phosphatase concentration in serum (expressed in U/L)	before and 300 minutes after 18F-PSMA administration
Biodistribution of 18F-PSMA	Follow up of 18F-PSMA distribution over time in blood, urine, and organs. 18F-PSMA	0 to 300 minutes after 18F-PSMA administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Establishment of critical organs	Based on the biodistribution of 18F-PSMA (primary outcome 14), it will be investigated which organs receive the highest radiation dose (expressed in mGy/MBq).	0 to 300 minutes after 18F-PSMA administration
Investigation of the stability of 18F-PSMA over time in plasma	The stability of 18F-PSMA will be assessed via measurement of the percentage defluorination of the compound. Free 18F will be separated from 18F-PSMA using solid-phase extraction, radioactivity (kBq/cc) of each fraction will be measured.	0 to 300 minutes after 18F-PSMA administration

Collaborators and Investigators

• Sponsor: University Hospital, Ghent

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 4, 2018
• Primary Completion (ACTUAL): March 27, 2018
• Study Completion (ACTUAL): March 29, 2018

Study Registration Dates

• First Submitted: February 1, 2018
• First Submitted That Met QC Criteria: June 14, 2018
• First Posted (ACTUAL): June 15, 2018

Study Record Updates

• Last Update Posted (ACTUAL): December 2, 2022
• Last Update Submitted That Met QC Criteria: November 29, 2022
• Last Verified: June 1, 2018

More Information

Terms related to this study

• Keywords: prostate cancer; biochemical recurrence; 18F-PET imaging
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms
• Other Study ID Numbers: AGO/2017/006; 2017-003461-96 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No